Data-driven analysis, regulatory trends, and strategic insights for pharmaceutical executives
A practical, step-by-step framework for evaluating and selecting a Contract Development and Manufacturing Organization — from capability mapping and FDA compliance screening to RFIs and risk scoring.
A plain-English guide to the three FDA enforcement signals every sourcing team should check before contracting a CMO, CDMO, or API supplier — what each one means, how serious it is, and how to act on it.
Analysis of the explosive growth in ADCs, recent multi-billion dollar acquisitions, and the technical hurdles for the next generation of 'Biological Missiles'.
Analysis of FDA approval patterns, accelerated pathways, and strategic implications for pharmaceutical companies in 2025.
Expert analysis of pharmaceutical licensing structures, deal terms, and negotiation strategies for business development teams.
A practical, step-by-step framework for evaluating and selecting a Contract Development and Manufacturing Organization — from capability mapping and FDA compliance screening to RFIs and risk scoring.
A plain-English guide to the three FDA enforcement signals every sourcing team should check before contracting a CMO, CDMO, or API supplier — what each one means, how serious it is, and how to act on it.
How to qualify an active pharmaceutical ingredient (API) supplier — from DMF and GMP verification to FDA compliance screening, audits, and supply-continuity planning.
CMO, CDMO, CRO, CDO — the contract manufacturing acronyms explained in plain English, with guidance on which type of partner fits your stage and program.
A sourcing-team comparison of the major contract manufacturing regions — cost, regulatory familiarity, lead times, and supply-chain risk across the United States, India, and Europe.
When does dual-sourcing your active pharmaceutical ingredient justify the cost and complexity? A framework for balancing supply-chain resilience against efficiency.
How the shift toward regional manufacturing hubs and the rise of multi-modality CDMOs are redefining the pharma outsourcing landscape in 2025.
Analysis of the explosive growth in ADCs, recent multi-billion dollar acquisitions, and the technical hurdles for the next generation of 'Biological Missiles'.
Exploring the regulatory incentives, pricing dynamics, and strategic opportunities in the rapidly expanding $200B orphan drug sector.
Analysis of FDA approval patterns, accelerated pathways, and strategic implications for pharmaceutical companies in 2025.
Expert analysis of pharmaceutical licensing structures, deal terms, and negotiation strategies for business development teams.
How artificial intelligence is accelerating drug discovery timelines and what pharma companies need to succeed with AI-first R&D.
Explore pharma data, clinical trial insights, and competitive intelligence workflows
Start free trial